Q-omics provides the consensus-scored INPP5J profile across patient tissues and cancer cell-line models. INPP5J expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, INPP5J is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, INPP5J RNA expression shows 18,082 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, KIRC, and TGCT as cancer lineages where INPP5J shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for INPP5J — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes INPP5J survival associations across molecular data types. INPP5J RNA expression shows survival associations in the most cancer types (26), followed by mutation status (10) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible INPP5J RNA expression–survival associations across cancer types. High INPP5J expression shows unfavorable associations in UVM, LIHC and MESO, but favorable associations in LUAD, READ and UCEC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for INPP5J RNA expression.
This table summarizes INPP5J tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for INPP5J. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. INPP5J shows lower tumor expression in KIRC, KIRP, THCA, COAD and LUAD and higher tumor expression in LIHC. The KIRC box plot shows higher INPP5J RNA expression in normal versus tumor tissue (log2 FC = −4.058, t-test p < 0.001).
This table shows molecular features associated with INPP5J in patient tissues and cancer cell lines. In patient samples, INPP5J shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, INPP5J RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BREAST.
